Medicine for treating hypertensive nephropathy and preparation method thereof
Through the combined use of traditional Chinese medicine compositions and captopril and α-ketoglutaric acid, the side effects and stability problems of captopril in the treatment of hypertensive nephropathy have been solved, and more effective antihypertensive and renal function improvement have been achieved. Significantly reduces proteinuria excretion.
Patent Information
- Application Number
- CN202411100599.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-12
AI Technical Summary
The existing Western medicine captopril has side effects and poor treatment stability in the treatment of hypertensive nephropathy, and cannot effectively cure the disease.
Using traditional Chinese medicine compositions, including Gastrodia elata, Uncaria, White marigold, Ashdolina, Sugaria sausage, Mulberry parasitology, Salvia miltiorrhiza, Peony red peony, Alisma and Safflower, combined with Captopril and α-ketoglutaric acid, through extraction and A mixture of concentrates is used to prepare drugs for the treatment of hypertensive nephropathy.
It significantly reduces the side effects of captopril, improves the treatment effect, achieves stable blood pressure reduction, improves renal function, reduces proteinuria excretion, prolongs treatment timeliness, and improves patient compliance.
Smart Images

Figure BDA0004989266580000153 
Figure BDA0004989266580000162
Abstract
Description
Technical Field
[0001] The present application relates to the field of medical technology, and more specifically, to a drug for treating hypertensive nephropathy and a preparation method thereof. Background Art
[0002] Hypertension is one of the common cardiovascular and cerebrovascular diseases. A long history of primary hypertension can cause kidney lesions. Hypertensive nephropathy refers to renal arteriosclerosis caused by hypertension, accompanied by varying degrees of renal failure, with edema, proteinuria, hypoproteinemia and hyperlipidemia as the main manifestations. In recent years, with the improvement of people's living standards and the extension of life expectancy, the incidence of hypertension (primary) has increased year by year, and hypertensive renal damage currently ranks at the forefront of the basic diseases of end-stage renal disease.
[0003] At present, Western medicine is commonly used in clinical practice to control blood pressure in combination with lifestyle intervention. However, Western medicine treatment of hypertensive nephropathy will have side effects of varying degrees, and it only treats the symptoms but not the root cause. Among them, Captopril tablets, as a renin angiotensin aldosterone receptor blocker, have the characteristics of low toxicity, good tolerance, and rapid onset compared with other antihypertensive drugs. It has become the first choice for the treatment of hypertensive nephropathy, and can quickly and effectively control blood pressure, thereby reducing damage to the kidneys. However, although Captopril is less toxic than other antihypertensive drugs, it still has certain toxic side effects. Because it contains -SH groups, it is very easy to cause dry cough; there may be penicillamine-like reactions, such as rash, eosinophilia, abnormal taste or loss, etc.; and there may be neutropenia, which often occurs in patients with long medication time, large doses or renal dysfunction. In addition, Captopril is a short-acting antihypertensive drug with a short half-life, which needs to be taken multiple times a day, poor antihypertensive stability, large blood pressure fluctuations, poor patient compliance, and cannot achieve effective treatment and radical cure. In view of this, the present application provides a drug for treating hypertensive nephropathy and a preparation method thereof. Summary of the invention
[0004] In order to solve the defects of the current Western medicine captopril in treating hypertensive nephropathy, such as side effects of varying degrees, poor treatment stability, poor patient compliance, and treating the symptoms but not the root cause, the present application provides a drug for treating hypertensive nephropathy and a preparation method thereof.
[0005] In the first aspect, the present application provides a drug for treating hypertensive nephropathy, using the following technical solution:
[0006] A medicine for treating hypertensive nephropathy, comprising a traditional Chinese medicine composition, which is prepared from the following components by weight: 1-15 parts of Gastrodia elata, 1-15 parts of Uncaria rhynchophylla, 10-35 parts of Imperata cylindrica, 1-15 parts of Cyathula officinalis, 1-5 parts of Prunella vulgaris, 1-15 parts of Taxillus parasiticus, 10-35 parts of Salvia miltiorrhiza, 1-15 parts of Paeonia lactiflora, 1-15 parts of Alismatis orientalis, and 1-15 parts of Carthamus tinctorius.
[0007] Preferably, the mass ratio of Achyranthes bidentata, Prunella vulgaris, Viscum album and Salvia miltiorrhiza is 3:1:3:7.
[0008] Preferably, the Chinese medicine composition is made of the following components in parts by mass: 10 parts of Gastrodia elata, 10 parts of Uncaria rhynchophylla, 25 parts of Imperata cylindrica, 12 parts of Cyathula capitata, 4 parts of Prunella vulgaris, 12 parts of Viscum album, 28 parts of Salvia miltiorrhiza, 10 parts of Paeonia lactiflora, 10 parts of Alismatis orientalis, and 2 parts of Carthamus tinctorius.
[0009] Preferably, the drug further comprises other active ingredients and pharmaceutically acceptable excipients;
[0010] The other active ingredients include captopril and alpha-ketoglutaric acid in a mass ratio of 1:5-7.
[0011] Preferably, the mass ratio of captopril to α-ketoglutaric acid is 1:5.8.
[0012] In a second aspect, the present application provides a method for preparing a drug for treating hypertensive nephropathy, using the following technical solution:
[0013] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0014] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0015] S2, soaking and extracting 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus altissima, Salvia miltiorrhiza, Paeonia rubra, Rhizoma Alismatis, and Carthamus tinctorius, filtering and combining the filtrates, and concentrating under reduced pressure to obtain a concentrate;
[0016] S3. Evenly mix the Gastrodia elata powder and the concentrated solution to obtain the desired medicine for treating hypertensive nephropathy.
[0017] Preferably, the specific operation in step S2 is as follows: add water to 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus alba, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:5-7, soak and extract at a temperature of 68-88°C for 1-3h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.20-1.30 (measured at 60°C) to obtain a concentrated solution.
[0018] Preferably, step S3 also includes other active ingredients and pharmaceutically acceptable excipients in the raw materials, and the specific operation is as follows: after uniformly mixing the Gastrodia elata powder, other active ingredients and pharmaceutically acceptable excipients, uniformly mixing with the concentrated solution, the desired drug for treating hypertensive nephropathy is obtained.
[0019] Preferably, the amount of the other active ingredients added is 0.1-0.2 times the mass of the Gastrodia elata micropowder, and the amount of the pharmaceutically acceptable excipients added is 5-6 times the mass of the Gastrodia elata micropowder.
[0020] Preferably, the drug for treating hypertensive nephropathy in step S3 is in the form of granules, tablets or capsules.
[0021] In summary, this application has the following beneficial effects:
[0022] In the Chinese medicine composition proposed in the present application, Gastrodia elata, Uncaria rhynchophylla, and Imperata cylindrica are used as the main drugs, which play the role of treating hypertensive nephropathy. Among them, Gastrodia elata contains the effective ingredient gastrodin, i.e., p-hydroxymethylphenol β-D-glucoside, and also contains p-hydroxybenzaldehyde, p-hydroxybenzyl alcohol, succinic acid, β-sitosterol, etc. Experiments have shown that gastrodin has the effects of sedation, anesthesia, anticonvulsant, intelligence, blood pressure reduction, enhancement of myocardial cell function, anti-inflammatory, enhancement of immune function, delay of aging, and mild enhancement of small intestinal peristalsis; Uncaria rhynchophylla can diuresis and reduce swelling, and is used to treat edema, nephritis and other diseases. Rhynchophylline and isorhynchophylline in Uncaria rhynchophylla can dilate peripheral blood vessels and assist in lowering blood pressure; Imperata cylindrica has the effect of diuresis and stranguria, and can assist in the treatment of hematuria caused by acute glomerulonephritis. The alkaloids and flavonoids in Imperata cylindrica can dilate blood vessels and lower blood pressure.
[0023] The invention adopts Chinese radix achyranthis Bidentatae, herba selfhei, herba villosae and salvia miltiorrhizae as the ministerial drugs, among which Chinese radix achyranthis Bidentatae has the effects of tonifying liver and kidney, promoting blood circulation, etc., can effectively lower blood pressure, blood lipid, improve liver function and enhance immunity; herba selfhei has the effects of detoxifying and clearing away heat, reducing swelling and dispersing knots, lowering blood pressure, clearing liver and improving eyesight, and the saponins and other substances contained in herba selfhei can promote blood circulation and strengthen myocardial function; herba villosae has the effects of removing rheumatism, tonifying liver and kidney, strengthening tendons and bones, lowering blood pressure, lowering blood lipid, calming, and diuresis, can dilate coronary arteries and increase coronary blood flow; the salvianolic acid, cinnamogenin and the like contained in salvia miltiorrhizae have multiple pharmacological effects, including dilating blood vessels, lowering blood pressure, enhancing myocardial contractility, improving microcirculation and the like; salvia miltiorrhizae can also activate the renin-angiotensin-aldosterone system, increase renal blood flow, and thus play a role in increasing renal blood flow; the addition of ministerial drugs can assist the monarch drugs in enhancing the therapeutic effect on the one hand, and on the other hand, by controlling the dosage ratio of each component of the ministerial drugs, the ministerial drugs themselves can also play a good therapeutic effect.
[0024] Red peony root and Alisma orientalis are used as adjuvants. Red peony root has the effects of soothing the liver, clearing away heat and cooling blood. It can improve cardiopulmonary function, dilate coronary arteries, increase coronary blood flow, and improve and lower blood pressure. Alisma orientalis can treat symptoms such as difficulty urinating, body edema, hyperlipidemia, hypertension, and hot and painful stranguria. The addition of both can assist the main and auxiliary drugs to enhance the efficacy.
[0025] Safflower is used as the adjuvant. Safflower itself does not have a significant blood pressure lowering effect, but it has the effects of promoting blood circulation and unblocking meridians, protecting blood vessels and liver, regulating endocrine disorders, increasing metabolism, and avoiding qi stagnation and blood stasis that aggravate kidney disease, so that the formula components can work synergistically.
[0026] This application combines the various medicinal ingredients according to the relationship between the monarch, minister, assistant and envoy of the drugs and uses them to treat hypertensive nephropathy. It is observed in many years of clinical practice that the conditions and clinical indicators of most patients are significantly improved. Compared with existing formulas, the efficacy is more reliable, and it is safe and has no obvious toxic side effects. This application is effective in lowering blood pressure and treating proteinuria caused by hypertensive nephropathy.
[0027] The medicine described in the present application uses a Chinese medicine composition and other active ingredients captopril and α-ketoglutaric acid in combination to jointly treat hypertensive nephropathy. The Chinese medicine composition can cooperate with captopril and α-ketoglutaric acid to significantly reduce the amount of captopril used, improve the therapeutic effect on hypertensive nephropathy, reduce or even offset toxic side effects, achieve stable blood pressure reduction, improve renal function levels, and reduce proteinuria excretion; the addition of α-ketoglutaric acid can further improve the therapeutic effect, prolong the treatment time, and improve patient compliance, thereby helping to achieve a radical effect and shorten the treatment cycle. DETAILED DESCRIPTION
[0028] The present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the scope of the present invention.
[0029] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0030] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.
[0031] Example 1-6 provides a drug for treating hypertensive nephropathy and a preparation method thereof.
[0032] Example 1
[0033] A medicine for treating hypertensive nephropathy, the raw materials of which include a Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
[0034] The Chinese medicine composition is prepared from the following components: 5 parts of Gastrodia elata, 5 parts of Uncaria rhynchophylla, 25 parts of Imperata cylindrica, 6 parts of Cyathula officinalis, 2 parts of Prunella vulgaris, 6 parts of Morus altissima, 14 parts of Salvia miltiorrhiza, 5 parts of Paeonia lactiflora, 5 parts of Orientalis alisma, and 5 parts of Carthamus tinctorius;
[0035] The pharmaceutically acceptable excipient is dextrin.
[0036] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0037] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0038] S2. Add water to 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus parasiticus, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:5, soak and extract at 68°C for 3h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.20 (measured at 60°C) to obtain a concentrate;
[0039] S3. Control the amount of dextrin added to be 5 times the mass of Gastrodia elata micropowder. After evenly mixing the Gastrodia elata micropowder and dextrin, add the concentrated solution and mix evenly to make granules together. After the granulation is completed, dry at 60°C to a moisture content of 5%. Use a 20-mesh sieve to granulate the granules to obtain the desired medicine for treating hypertensive nephropathy.
[0040] Example 2
[0041] A medicine for treating hypertensive nephropathy, the raw materials of which include a Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
[0042] The Chinese medicine composition is prepared from the following components: 10 parts of Gastrodia elata, 8 parts of Uncaria rhynchophylla, 28 parts of Imperata cylindrica, 12 parts of Cyathula officinalis, 3 parts of Prunella vulgaris, 12 parts of Morus parasiticus, 21 parts of Salvia miltiorrhiza, 10 parts of Paeonia lactiflora, 10 parts of Orientalis alisma, and 8 parts of Carthamus tinctorius;
[0043] The pharmaceutically acceptable excipient is dextrin.
[0044] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0045] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0046] S2. Add water to 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus parasiticus, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:5.5, soak and extract at 73°C for 2.5h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.20 (measured at 60°C) to obtain a concentrate;
[0047] S3. Control the amount of dextrin added to be 5.5 times the mass of Gastrodia elata micropowder. After evenly mixing the Gastrodia elata micropowder and dextrin, add the concentrated solution and mix evenly to make granules together. After the granulation is completed, dry at 65°C to a moisture content of 3%. Use a 20-mesh sieve to sieve the granules to obtain the desired medicine for treating hypertensive nephropathy.
[0048] Example 3
[0049] A medicine for treating hypertensive nephropathy, the raw materials of which include a Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
[0050] The Chinese medicine composition is prepared from the following components: 10 parts of Gastrodia elata, 10 parts of Uncaria rhynchophylla, 25 parts of Imperata cylindrica, 12 parts of Cyathula officinalis, 4 parts of Prunella vulgaris, 12 parts of Morus parasiticus, 28 parts of Salvia miltiorrhiza, 10 parts of Paeonia lactiflora, 10 parts of Orientalis alisma, and 2 parts of Carthamus tinctorius;
[0051] The pharmaceutically acceptable excipient is dextrin.
[0052] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0053] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0054] S2. Add water to 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus parasiticus, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:6, soak and extract at 78°C for 2h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.30 (measured at 60°C) to obtain a concentrate;
[0055] S3. Control the amount of dextrin added to be 6 times the mass of Gastrodia elata micropowder. After evenly mixing the Gastrodia elata micropowder and dextrin, add the concentrated solution and mix evenly to make granules together. After the granulation is completed, dry at 70°C to a moisture content of 3%. Use a 20-mesh sieve to sieve the granules to obtain the desired medicine for treating hypertensive nephropathy.
[0056] Example 4
[0057] A medicine for treating hypertensive nephropathy, the raw materials of which include a Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
[0058] The Chinese medicine composition is prepared from the following components: 15 parts of Gastrodia elata, 15 parts of Uncaria rhynchophylla, 35 parts of Imperata cylindrica, 15 parts of Cyathula officinalis, 5 parts of Prunella vulgaris, 15 parts of Morus parasiticus, 35 parts of Salvia miltiorrhiza, 15 parts of Paeonia lactiflora, 12 parts of Orientalis alisma, and 8 parts of Carthamus tinctorius;
[0059] The pharmaceutically acceptable excipient is dextrin.
[0060] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0061] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0062] S2. Add water to 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus parasiticus, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:7, soak and extract at 88°C for 1h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.30 (measured at 60°C) to obtain a concentrate;
[0063] S3. Control the amount of dextrin added to be 6 times the mass of Gastrodia elata micropowder. After evenly mixing the Gastrodia elata micropowder and dextrin, add the concentrated solution and mix evenly to make granules together. After the granulation is completed, dry at 70°C to a moisture content of 3%. Use a 20-mesh sieve to sieve the granules to obtain the desired medicine for treating hypertensive nephropathy.
[0064] Example 5
[0065] A medicine for treating hypertensive nephropathy, the raw materials of which include a Chinese medicine composition, other active ingredients and pharmaceutically acceptable excipients.
[0066] The Chinese medicine composition is prepared from the following components: 5 parts of Gastrodia elata, 5 parts of Uncaria rhynchophylla, 25 parts of Imperata cylindrica, 6 parts of Cyathula officinalis, 2 parts of Prunella vulgaris, 6 parts of Morus altissima, 14 parts of Salvia miltiorrhiza, 5 parts of Paeonia lactiflora, 5 parts of Orientalis alisma, and 5 parts of Carthamus tinctorius;
[0067] Other active ingredients include captopril and α-ketoglutarate in a mass ratio of 1:5;
[0068] The pharmaceutically acceptable excipient is dextrin.
[0069] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0070] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0071] S2. Add water to 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus parasiticus, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:5, soak and extract at 68°C for 3h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.20 (measured at 60°C) to obtain a concentrate;
[0072] S3. Control the amount of dextrin added to be 5 times the mass of Gastrodia elata micropowder, and the amount of other active ingredients added to be 0.1 times the mass of Gastrodia elata micropowder. After uniformly mixing Gastrodia elata micropowder, other active ingredients and pharmaceutically acceptable excipients, add concentrated solution and mix uniformly, and granulate together. After granulation, dry at 60°C to a moisture content of 5%, and sieve through a 20-mesh sieve to obtain the desired medicine for treating hypertensive nephropathy.
[0073] Example 6
[0074] A medicine for treating hypertensive nephropathy, the raw materials of which include a Chinese medicine composition, other active ingredients and pharmaceutically acceptable excipients.
[0075] The Chinese medicine composition is prepared from the following components: 5 parts of Gastrodia elata, 5 parts of Uncaria rhynchophylla, 25 parts of Imperata cylindrica, 6 parts of Cyathula officinalis, 2 parts of Prunella vulgaris, 6 parts of Morus altissima, 14 parts of Salvia miltiorrhiza, 5 parts of Paeonia lactiflora, 5 parts of Orientalis alisma, and 5 parts of Carthamus tinctorius;
[0076] Other active ingredients include captopril and α-ketoglutarate in a mass ratio of 1:7;
[0077] The pharmaceutically acceptable excipient is dextrin.
[0078] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0079] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0080] S2. Add water to 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus parasiticus, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:5, soak and extract at 68°C for 3h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.20 (measured at 60°C) to obtain a concentrate;
[0081] S3. Control the amount of dextrin added to be 5 times the mass of Gastrodia elata micropowder, and the amount of other active ingredients added to be 0.2 times the mass of Gastrodia elata micropowder. After uniformly mixing Gastrodia elata micropowder, other active ingredients and pharmaceutically acceptable excipients, add concentrated solution and mix uniformly, and granulate together. After granulation, dry at 60°C to a moisture content of 5%, and sieve through a 20-mesh sieve to obtain the desired medicine for treating hypertensive nephropathy.
[0082] In order to verify the therapeutic effect of the drugs for treating hypertensive nephropathy prepared in Examples 1-6 of the present application, the applicant set up Comparative Examples 1-5, which are as follows:
[0083] Comparative Example 1
[0084] A medicine for treating hypertensive nephropathy, the raw materials of which include a Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
[0085] The Chinese medicine composition is prepared from the following components: 5 parts of Gastrodia elata, 5 parts of Uncaria rhynchophylla, 25 parts of Imperata cylindrica, 6 parts of Cyathula officinalis, 2 parts of Prunella vulgaris, 6 parts of Morus altissima, 14 parts of Salvia miltiorrhiza, 5 parts of Paeonia lactiflora, and 5 parts of Alismatis;
[0086] The pharmaceutically acceptable excipient is dextrin.
[0087] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0088] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0089] S2. Add water to 8 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus alba, Salvia miltiorrhiza, Paeonia lactiflora and Rhizoma Alismatis, control the solid-liquid ratio to 1:5, soak and extract at 68°C for 3h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.20 (measured at 60°C) to obtain a concentrate;
[0090] S3. Control the amount of dextrin added to be 5 times the mass of Gastrodia elata micropowder. After evenly mixing the Gastrodia elata micropowder and dextrin, add the concentrated solution and mix evenly to make granules together. After the granulation is completed, dry at 60°C to a moisture content of 5%. Use a 20-mesh sieve to granulate the granules to obtain the desired medicine for treating hypertensive nephropathy.
[0091] Comparative Example 2
[0092] A medicine for treating hypertensive nephropathy, the raw materials of which include a Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
[0093] The Chinese medicine composition is prepared from the following components: 5 parts of Gastrodia elata, 5 parts of Uncaria rhynchophylla, 25 parts of Imperata cylindrica, 7 parts of Cyathula officinalis, 7 parts of Prunella vulgaris, 7 parts of Morus alba, 7 parts of Salvia miltiorrhiza, 5 parts of Paeonia lactiflora, 5 parts of Orientalis alisma, and 5 parts of Carthamus tinctorius;
[0094] The pharmaceutically acceptable excipient is dextrin.
[0095] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0096] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0097] S2. Add water to 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus parasiticus, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:5, soak and extract at 68°C for 3h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.20 (measured at 60°C) to obtain a concentrate;
[0098] S3. Control the amount of dextrin added to be 5 times the mass of Gastrodia elata micropowder. After evenly mixing the Gastrodia elata micropowder and dextrin, add the concentrated solution and mix evenly to make granules together. After the granulation is completed, dry at 60°C to a moisture content of 5%. Use a 20-mesh sieve to granulate the granules to obtain the desired medicine for treating hypertensive nephropathy.
[0099] Comparative Example 3
[0100] A medicine for treating hypertensive nephropathy, the raw materials of which include a Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
[0101] The Chinese medicine composition is prepared from the following components: 5 parts of Gastrodia elata, 5 parts of Uncaria rhynchophylla, 25 parts of Imperata cylindrica, 6 parts of Cyathula officinalis, 6 parts of Morus alba, 14 parts of Salvia miltiorrhiza, 5 parts of Paeonia lactiflora, 5 parts of Orientalis alisma and 5 parts of Carthamus tinctorius;
[0102] The pharmaceutically acceptable excipient is dextrin.
[0103] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0104] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0105] S2, add water to 8 medicinal materials including Uncaria rhynchophylla, Imperata root, Achyranthes bidentata, Morus alba, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:5, soak and extract at 68°C for 3h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.20 (measured at 60°C) to obtain a concentrate;
[0106] S3. Control the amount of dextrin added to be 5 times the mass of Gastrodia elata micropowder. After evenly mixing the Gastrodia elata micropowder and dextrin, add the concentrated solution and mix evenly to make granules together. After the granulation is completed, dry at 60°C to a moisture content of 5%. Use a 20-mesh sieve to granulate the granules to obtain the desired medicine for treating hypertensive nephropathy.
[0107] Comparative Example 4
[0108] A medicine for treating hypertensive nephropathy, the raw materials of which include a Chinese medicine composition, other active ingredients and pharmaceutically acceptable excipients.
[0109] The Chinese medicine composition is prepared from the following components: 5 parts of Gastrodia elata, 5 parts of Uncaria rhynchophylla, 25 parts of Imperata cylindrica, 6 parts of Cyathula officinalis, 2 parts of Prunella vulgaris, 6 parts of Morus altissima, 14 parts of Salvia miltiorrhiza, 5 parts of Paeonia lactiflora, 5 parts of Orientalis alisma, and 5 parts of Carthamus tinctorius;
[0110] The other active ingredients are captopril;
[0111] The pharmaceutically acceptable excipient is dextrin.
[0112] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0113] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0114] S2. Add water to 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus parasiticus, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:5, soak and extract at 68°C for 3h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.20 (measured at 60°C) to obtain a concentrate;
[0115] S3. Control the amount of dextrin added to be 5 times the mass of Gastrodia elata micropowder, and the amount of other active ingredients added to be 0.1 times the mass of Gastrodia elata micropowder. After uniformly mixing Gastrodia elata micropowder, other active ingredients and pharmaceutically acceptable excipients, add concentrated solution and mix uniformly, and granulate together. After granulation, dry at 60°C to a moisture content of 5%, and sieve through a 20-mesh sieve to obtain the desired medicine for treating hypertensive nephropathy.
[0116] Comparative Example 5
[0117] A medicine for treating hypertensive nephropathy, the raw materials of which include a Chinese medicine composition, other active ingredients and pharmaceutically acceptable excipients.
[0118] The Chinese medicine composition is prepared from the following components: 5 parts of Gastrodia elata, 5 parts of Uncaria rhynchophylla, 25 parts of Imperata cylindrica, 6 parts of Cyathula officinalis, 2 parts of Prunella vulgaris, 6 parts of Morus altissima, 14 parts of Salvia miltiorrhiza, 5 parts of Paeonia lactiflora, 5 parts of Orientalis alisma, and 5 parts of Carthamus tinctorius;
[0119] The other active ingredients are alpha-ketoglutarate;
[0120] The pharmaceutically acceptable excipient is dextrin.
[0121] A method for preparing a drug for treating hypertensive nephropathy, comprising the following preparation steps:
[0122] S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use;
[0123] S2. Add water to 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus parasiticus, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:5, soak and extract at 68°C for 3h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.20 (measured at 60°C) to obtain a concentrate;
[0124] S3. Control the amount of dextrin added to be 5 times the mass of Gastrodia elata micropowder, and the amount of other active ingredients added to be 0.1 times the mass of Gastrodia elata micropowder. After uniformly mixing Gastrodia elata micropowder, other active ingredients and pharmaceutically acceptable excipients, add concentrated solution and mix uniformly, and granulate together. After granulation, dry at 60°C to a moisture content of 5%, and sieve through a 20-mesh sieve to obtain the desired medicine for treating hypertensive nephropathy.
[0125] Treatment effectiveness testing
[0126] The therapeutic effect tests were performed on the drugs for treating hypertensive nephropathy prepared in Examples 1-6 of the present application and Comparative Examples 1-5, respectively.
[0127] Effect Example 1: Effect of improving blood pressure in spontaneously hypertensive rats (SHR)
[0128] Sixty-five healthy male SHR rats (12-13 weeks old) and five normal Wistar rats of the same age were purchased from Beijing Sibeifu Biotechnology Co., Ltd., with animal certificate number: SCXK (Beijing) 2019-0010.
[0129] 65 SHR rats were randomly divided into 11 experimental groups, 1 hypertension model group and 1 captopril control group, with 5 rats in each group. The 11 experimental groups were respectively administered with the drugs for treating hypertensive nephropathy prepared in Examples 1-6 of the present application and Comparative Examples 1-5, with each group receiving a dosage of 6 mg / kg / d, and the captopril control group was administered with a dosage of 12.5 mg / kg / d. Normal Wistar rats of the same age were used as the normal control group, and the normal control group and the hypertension model group were gavaged with an equal volume of normal saline for 5 consecutive weeks.
[0130] During the 1-3 weeks of drug administration, the non-invasive rat tail blood pressure meter (BP-2000SERIESⅡ) was used to perform blood pressure measurement training for 30 minutes every day from 9:00 to 12:00 a.m. to adapt the animals to the blood pressure monitoring environment. The systolic and diastolic blood pressures were monitored 1 hour after drug administration in the 3rd, 4th and 5th weeks (9:00 to 12:00 a.m.), and the monitoring results are shown in Table 1-2 below.
[0131] All data were statistically analyzed using SPSS 25.0 software. The t test was used, and P < 0.05 was considered statistically significant.
[0132] Table 1 Effects on systolic blood pressure in spontaneously hypertensive rats (SHR) (n=7-10, )
[0133]
[0134] Note: Different letters represent P < 0.05.
[0135] Table 2 Effects on diastolic blood pressure in spontaneously hypertensive rats (SHR) (n=7-10, )
[0136]
[0137] Note: Different letters represent P < 0.05.
[0138] From the data shown in Table 1-2 above, it can be seen that the experimental groups of Examples 1-6 can significantly reduce the systolic and diastolic blood pressure of spontaneously hypertensive rats, and the antihypertensive effect is comparable to that of the captopril control group, and is significantly better than that of the experimental groups of Comparative Examples 1-5, showing a strong antihypertensive effect.
[0139] Effect Example 2: Improvement of renal damage caused by spontaneously hypertensive rats (SHR)
[0140] The serum of the animals from the same batch was taken, and the levels of serum β2-microglobulin (β2-MG) (Jiangsu ELISA, MM-21246R1), microalbumin (mALB) (Jiangsu ELISA, MM-70785R1) and N-acetylglucosidase (NAG) (Nanjing Jiancheng, A031-1-1) were detected by ELISA kits.
[0141] Table 3 Improvement effect on renal damage caused by spontaneously hypertensive rats (SHR)
[0142] Group β2-MG (μg / L) mALB (μg / L) NAG (μg / L) Normal control group <![CDATA[38.5±1.2 a ]]> <![CDATA[314.3±19.2 a ]]> <![CDATA[10.5±3.6 a ]]> Hypertension model group <![CDATA[57.1±4.0 b ]]> <![CDATA[301.5±10.2 b ]]> <![CDATA[42.0±12.6 b ]]> Example 1 Experimental Group <![CDATA[41.5±5.2 c ]]> <![CDATA[299.2±3.6 c ]]> <![CDATA[16.5±4.9 c ]]> Example 2 Experimental Group <![CDATA[40.4±3.7 c ]]> <![CDATA[298.9±4.4 c ]]> <![CDATA[16.1±5.4 c ]]> Example 3 Experimental Group <![CDATA[39.3±2.6 c ]]> <![CDATA[298.1±3.5 c ]]> <![CDATA[15.6±5.5 c ]]> Example 4 Experimental Group <![CDATA[40.6±4.6 c ]]> <![CDATA[299.7±4.1 c ]]> <![CDATA[16.4±6.4 c ]]> Example 5 Experimental Group <![CDATA[41.0±4.3 c ]]> <![CDATA[298.8±3.7 c ]]> <![CDATA[16.8±6.3 c ]]> Example 6 Experimental Group <![CDATA[41.3±6.1 c ]]> <![CDATA[299.0±3.5 c ]]> <![CDATA[17.0±5.4 c ]]> Comparative Example 1 Experimental Group <![CDATA[49.3±4.7 d ]]> <![CDATA[293.9±4.8 d ]]> <![CDATA[30.7±4.7 d <!-- 9 -->]]> Comparative Example 2 Experimental Group <![CDATA[48.8±5.6 d ]]> <![CDATA[291.4±5.3 d ]]> <![CDATA[31.1±5.4 d ]]> Comparative Example 3 Experimental Group <![CDATA[49.9±5.1 d ]]> <![CDATA[290.9±5.1 d ]]> <![CDATA[31.9±4.7 d ]]> Comparative Example 4 Experimental Group <![CDATA[50.7±4.6 d ]]> <![CDATA[292.7±6.0 d ]]> <![CDATA[32.2±4.9 d ]]> Comparative Example 5 Experimental Group <![CDATA[48.5±4.8 d ]]> <![CDATA[294.0±5.6 d ]]> <![CDATA[30.5±5.3 d ]]> Captopril control group <![CDATA[43.0±5.2 e ]]> <![CDATA[283.2±2.5 e ]]> <![CDATA[19.6±8.9 e ]]>
[0143] Note: Different letters represent P < 0.05.
[0144] From the data shown in Table 3 above, it can be seen that compared with the normal control group, the urine β2-MG and NAG of the rats in the hypertension model group were significantly increased, indicating that the SHR rats had kidney damage; and compared with the hypertension model group, after 5 weeks of administration of the experimental groups of Examples 1-6 and the captopril control group, the levels of urine β2-MG and NAG were significantly reduced, and the mALB level did not change significantly. The experimental groups of Examples 1-6 of the present application can significantly improve the renal tubular damage caused by spontaneously hypertensive rats.
[0145] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.
Claims
1. A drug for treating hypertensive nephropathy, characterized in that: The medicine comprises a traditional Chinese medicine composition, which is made of the following components by weight: 1-15 parts of Gastrodia elata, 1-15 parts of Uncaria rhynchophylla, 10-35 parts of Imperata cylindrica, 1-15 parts of Achyranthes bidentata, 1-5 parts of Prunella vulgaris, 1-15 parts of Taxillus parasiticus, 10-35 parts of Salvia miltiorrhiza, 1-15 parts of Paeonia lactiflora, 1-15 parts of Alismatis orientalis, and 1-15 parts of Carthamus tinctorius.
2. The drug for treating hypertensive nephropathy according to claim 1, characterized in that: The mass ratio of Polygonum multiflorum, Prunella vulgaris, Viscum album and Salvia miltiorrhiza is 3:1:3:
7.
3. The drug for treating hypertensive nephropathy according to claim 2, characterized in that: The traditional Chinese medicine composition is made of the following components by mass: 10 parts of Gastrodia elata, 10 parts of Uncaria rhynchophylla, 25 parts of Imperata cylindrica, 12 parts of Cyathula officinalis, 4 parts of Prunella vulgaris, 12 parts of Morus alba, 28 parts of Salvia miltiorrhiza, 10 parts of Paeonia lactiflora, 10 parts of Alismatis orientalis, and 2 parts of Carthamus tinctorius.
4. The drug for treating hypertensive nephropathy according to claim 1, characterized in that: The drug also contains other active ingredients and pharmaceutically acceptable excipients; The other active ingredients include captopril and alpha-ketoglutaric acid in a mass ratio of 1:5-7.
5. A method for preparing the drug for treating hypertensive nephropathy according to any one of claims 1 to 4, characterized in that: The method comprises the following preparation steps: S1. Grind the Gastrodia elata into fine powder, pass it through a 150-mesh sieve, and obtain the Gastrodia elata fine powder for later use; S2, soaking and extracting 9 medicinal materials including Uncaria rhynchophylla, Imperata cylindrica, Achyranthes bidentata, Prunella vulgaris, Morus altissima, Salvia miltiorrhiza, Paeonia rubra, Rhizoma Alismatis, and Carthamus tinctorius, filtering and combining the filtrates, and concentrating under reduced pressure to obtain a concentrate; S3. Evenly mix the Gastrodia elata powder and the concentrated solution to obtain the desired medicine for treating hypertensive nephropathy.
6. The method for preparing the drug for treating hypertensive nephropathy according to claim 5, characterized in that: The specific operation in step S2 is as follows: add water to 9 medicinal materials including Uncaria rhynchophylla, Imperata root, Achyranthes bidentata, Prunella vulgaris, Morus parasiticus, Salvia miltiorrhiza, Paeonia lactiflora, Rhizoma Alismatis, and Carthamus tinctorius, control the solid-liquid ratio to 1:5-7, soak and extract at a temperature of 68-88°C for 1-3h, filter, repeat the extraction 3 times, combine the filtrate, and concentrate under reduced pressure to a relative density of 1.20-1.30 (measured at 60°C) to obtain a concentrated solution.
7. The method for preparing the drug for treating hypertensive nephropathy according to claim 5, characterized in that: The step S3 also includes other active ingredients and pharmaceutically acceptable excipients, and the specific operation is as follows: after the Gastrodia elata powder, other active ingredients and pharmaceutically acceptable excipients are evenly mixed, they are evenly mixed with the concentrated solution to obtain the desired drug for treating hypertensive nephropathy.
8. The method for preparing the drug for treating hypertensive nephropathy according to claim 7, characterized in that: The addition amount of the other active ingredients is 0.1-0.2 times the mass of the Gastrodia elata micropowder, and the addition amount of the pharmaceutically acceptable excipients is 5-6 times the mass of the Gastrodia elata micropowder.
9. The method for preparing the drug for treating hypertensive nephropathy according to claim 5, characterized in that: The drug granules, tablets or capsules for treating hypertensive nephropathy in step S3.
Citation Information
Patent Citations
Medicinal composition with blood glucose reducing, blood lipid reducing and blood pressure lowering effects
CN103800639A
Traditional Chinese medicine used for treating hypertension
CN104688956A
Traditional Chinese medicine composition for treating hypertension and preparation method thereof
CN114246896A
